Cardiovascular disease: risk assessment and reduction, including lipid modification (CG181) - guidance update

This guidance has been updated to incorporate inclisiran, recommended in NICE TA733 as an option for treating primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia in patients with set restrictions.

SPS commentary:

Inclisiran is restricted to use where:

 

  • There is a history of any of the following cardiovascular events:
    • acute coronary syndrome (such as myocardial infarction or unstable angina needing hospitalisation)
    • coronary or other arterial revascularisation procedures
    • coronary heart disease
    • ischaemic stroke or
    • peripheral arterial disease

And

  • Low-density lipoprotein cholesterol (LDL-C) concentrations are persistently 2.6 mmol/l or more, despite maximum tolerated lipid-lowering therapy, that is:
    • maximum tolerated statins with or without other lipid-lowering therapies or,
    • other lipid-lowering therapies when statins are not tolerated or are contraindicated

National Institute for Health and Care Excellence

Resource links:

NICE TA733: Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia